SIMBRINZA

Alcon Laboratories, Inc.🇺🇸 United States

FDA Page

Effective Date: May 16, 2023
Approval ID: a49c157e-6310-0011-7b7f-e26fc1820d59
Products: 1 registered
Version: 18

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use SIMBRINZA safely and effectively. See full prescribing information for SIMBRINZA. SIMBRINZA (brinzolamide and brimonidine tartrate ophthalmic suspension) 1%/0.2%, for topical ophthalmic use Initial U.S. Approval: 2013

Quick Stats

Total Products1

Labelers2

Label Sections17

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.